The last battle of Alessandro Farnese (1545-1592) Some medical considerations regarding the health of the Renaissance leader who changed Europe

Main Article Content

Emanuele Armocida
Graziella Masciangelo
Ovidio Bussolati

Keywords

Alessandro Farnese 3rd Duke of Parma and Piacenza, Reanissance, hepatosplenomegaly, autopsy, spontaneous bacterial peritonitis, history of medicine, pancreas

Abstract

Background and aim: Alessandro Farnese (1545-1592), 3rd Duke of Parma and Piacenza, one of the most important generals and politicians of his age. He died after a rapid deterioration of his health. The available documents testify that the Duke suffered for a long time from various health problems, such as jaundice, intestinal disorders, gout, dropsy but very little is known about the cause(s) of his death. The aim of this article is to offer for the first time a complete clinical interpretation of Alessandro Farnese’s last months of life


Methods: A collection of descriptions of symptoms and signs described by his court physician and by the leading biographers of Farnese has been compiled. This collected medical evidence has been interpreted in the light of current medical knowledge, to obtain a final interpretation.


Results: The results led us to consider liver diseases, neoplastic diseases (especially pancres) and infectious diseases (including typhus and malaria) as causes or contributing causes of death.


Conclusions: The accurate autopsy description, in association with the anamnestic information provided by the historical documents studied, suggests that Alessandro Farnese was a hepatopathic patient suffering from spontaneous bacterial peritonitis. In the pre-antibiotic era, the pathological organ alterations described certainly have at least contributed to making the infectious episode (that the autopsy describes of pulmonary origin) fatal.

Downloads

Download data is not yet available.
Abstract 96 | PDF Downloads 70

References

1. Drei G. I Farnese: grandezza e decadenza di una dinastia italiana. Roma: La Libreria dello Stato; 1954.
2. Fea P. Alessandro Farnese il duca di Parma: Narrazione storica e militare scritta colla scorta di documenti inediti. Torino: Fratelli Bocca;1886.
3. Fea P. Alessandro Farnese il duca di Parma: Narrazione storica e militare scritta colla scorta di documenti inediti. Torino: Fratelli Bocca; 1886. p.320-321.
4. Fea P. [Alessandro Farnese in Nederland]. La Rassegna nazionale. 1885; 23: 387-432. Italian
5. Archivio Storico di Parma, Raccolta di Manoscritti, Documenti per la storia della medicina, 133, lettera da Ippolito Pennone a Ranuccio Farnese.
6. Peracchia M, Meleti M, Armocida E, et al. Oral status of a noble European couple from the 16th century: A morphologic analysis of the teeth of Alessandro Farnese and his wife Maria D’Aviz. Anthropologischer Anzeiger. 2022; 79(1):69–81.
7. Fea P. Alessandro Farnese il duca di Parma: Narrazione storica e militare scritta colla scorta di documenti inediti. Torino: Fratelli Bocca; 1886. p.457-458.
8. Giurleo F. La famiglia Farnese. Terni: Edizioni ArcheoAres; 2014.
9. Dall'Acqua M. Ranuccio I Farnese, 1569-1622 : il duca che scrutava le ombre, in Bertini G. editor. Storia di Parma : vol. IV : Il ducato farnesiano. Parma: Monte Università Parma Editore; 2014. p. 113-147.
10. Caro A. Delle lettere del commendatore Annibal Caro. Vol. 1. Appresso G. Comino; 1765.
11. Dalvi SR, Pillinger MH. Saturnine gout, redux: a review. Am J Med. 2013; 126(5): 450-e1.
12. Fea P. Alessandro Farnese il duca di Parma: Narrazione storica e militare scritta colla scorta di documenti inediti. Torino: Fratelli Bocca; 1886. p.230.
13. Schuppan D, Afdhal NH. Liver cirrhosis. The Lancet, 2008; 371(9615): 838-851.
14. Xiao P, He L, Wang L. Ethnopharmacologic study of Chinese rhubarb. J Ethnopharmacol. 1984; 10(3): 275-293.
15. Mahpour NY, Pioppo-Phelan L, Reja M, Tawadros A, Rustgi VK. Pharmacologic management of hepatic encephalopathy. Clin Liver Dis. 2020; 24(2): 231-242.
16. Harding DJ, Perera MT, Chen F, Olliff S, Tripathi D. Portal vein thrombosis in cirrhosis: Controversies and latest developments. World J Gastroenterol. 2015;21(22):6769-84.
17. Bernardi M. Spontaneous bacterial peritonitis: from pathophysiology to prevention. Intern Emerg Med. 2010; 5(1): 37-44.
18. Ponsioen CY. Diagnosis, differential diagnosis, and epidemiology of primary sclerosing cholangitis. Dig. Dis. 2015; 33(Suppl. 2): 134-139.
19. Członkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers. 2018; 4(1):21.
20. Coccolini F. et al. Peritoneal carcinomatosis. World J Gastroenterol. 2013;19(41):6979-94.
21. Busnardo AC, Di Dio LJ, Tidrick RT, Thomford NR. History of the pancreas. Am J Surg. 1983;146(5): 539-550.
22. Thomassen I. et al. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study. Pancreas, 2013; 42(1): 72-75.
23. Holly EA, Chaliha I, Bracci PM, Gautam M. Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area. Clin Gastroenterol Hepatol. 2004;2(6): 510-517.
24. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846-4861.
25. Sinton JA. Malaria in war. Ulster Med J. 1946; 15(1), 3-28.
26. Warrell DA. Clinical features of malaria. In: Essential malariology. CRC Press, 2017. p. 191-205.
27. Garcia LS. Malaria. Clin Lab Med. 2010 Mar;30(1):93-129.
28. Nsutebu EF, Martins P, Adiogo D. Prevalence of typhoid fever in febrile patients with symptoms clinically compatible with typhoid fever in Cameroon. Trop Med Int Health. 2003;8(6): 575-578.